ADAM17与HER-2在乳腺癌中表达的意义及相关性

目的探讨解聚素-金属蛋白酶17(a disintegrin and metalloproteinase 17,ADAM17)和原癌基因人表皮生长因子受体2(human epidermal growth factor receptor-2,HER-2)在乳腺癌中的表达及相关性,探索新的乳腺肿瘤标记物。方法采用免疫组化法检测ADAM17和HER-2在正常乳腺组织及乳腺癌中的表达情况,并分析其表达与临床病理关系。结果 ADAM17和HER-2在正常乳腺组织中的表达以阴性为主,少部分呈弱阳性表达;而在乳腺癌中表达增高,以阳性表达为主,且强阳性占大部分,差异有统计学意义(P<0.05),两者在乳腺癌中的表达存在正相关性。ADAM17与HER-2表达水平与乳腺癌患者的年龄及肿瘤大小无关,而与腋窝淋巴结转移有关。结论 ADAM17和HER-2在乳腺癌中的表达增高,且两者的表达水平均可反映癌细胞的淋巴结转移能力,因此ADAM17可成为一个乳腺癌靶向治疗的新靶点。

Expression of ADAM17 and HER-2 in breast cancer and their correlation

Objective To investigate the expressions and clinical significance of a disintegrin and metalloproteinase 17(ADAM17) and human epidermal growth factor receptor-2(HER-2) in human breast cancer;and to investigated the correlation between ADAM17 and HER-2.Methods The expression of ADAM17 and HER-2 in the normal breast tissue and breast cancer were detected by immunohistochemical staining.Results ADAM17 and HER-2 were negatively or weakly expressed in normal breast tissue,while the expression was positive in breast cancer.The ADAM17 and HER-2 positive expression rates in breast cancer were significantly higher than those in normal tissues(P<0.05).There was no significant correlation between expression of ADAM17 or HER-2 and the age of patients or tumor size.However,there was significant correlation between the expressions of ADAM17 or HER-2 and lymph node metastasis.Conclusions The expressions of ADAM17 and HER-2 are associated with the biological characteristics of breast cancer,indicating possible lymph node metastasis.Thus ADAM17 provides new target for breast cancer treatment.